A Phase I Study of NVL-520 in People with Solid Tumors


Full Title

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)


The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth


To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a metastatic solid tumor that has an ROS1 fusion, such as non-small cell lung cancer.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Alexander Drilon at 646-608-3758.





Disease Status

Relapsed or Refractory